Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

Treatments: Drug: AZD 1775

Study type: Interventional

Funder types: Industry

Identifiers

NCT02482311

REFMAL 383 (Other Identifier)

D6015C00001

Details and patient eligibility

About

This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.

Full description

This study is being conducted in two parts, designated Parts A and B. Part A is a safety lead-in consisting of a cohort of approximately 12 patients with advanced solid tumours.

Part B expansion cohorts will investigate AZD1775 monotherapy in advanced tumour types with molecular biomarkers of interest. The tumour types to be evaluated are: 1) ovarian cancer (BRCA1/2 mutation [PARP-failures]), 2) ovarian cancer (BRCA wild-type) with more than three prior lines of treatment, 3) triple negative breast cancer (TNBC), and 4) small-cell lung cancer (SCLC).

Enrollment: 92 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18

2. Previous chemotherapy for recurrent or metastatic disease.

3. Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria.

4. Radiation therapy completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects.

5. ECOG Performance Status (PS) score of 0-1.

6. Baseline laboratory values as follows:

   1. ANC ≥1500/μL
   2. Hgb ≥9 g/dL
   3. Platelets ≥100,000/μL
   4. ALT and AST ≤3 x ULN or ≤5 x ULN if known hepatic metastases.
   5. Serum bilirubin WNL or ≤1.5 x the ULN in patients with liver metastases; or total bilirubin ≤3.0 x ULN with direct bilirubin WNL in patients with well documented Gilbert's Syndrome.
   6. Serum creatinine ≤1.5 x the ULN and a calculated creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method.

7. Negative serum or urine pregnancy test within 3 days prior to start of study treatment.

8. Fertile male patients willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops.

9. Predicted life expectancy ≥12 weeks.

Inclusion Criteria Specific for Part A:

1. Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
2. Has agreed to the collection of archival tumour tissue or recent tumour biopsy tissue, it taken for routine clinical purposes at baseline if archival tissue is not available, for molecular biomarker analyses.

Inclusion Criteria Specific for Part B:

1. Ovarian cancer defined as a histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer refractory to standard therapies of for which no standard therapy exists. Confirmed BRCA1 or BRCA2 mutation from a prior test. Patient progressed while receiving and/or following treatment with a PARP-inhibitor for advanced disease (recurrent or metastatic.
2. Ovarian cancer confirmed BRCA wild-type from a prior test.
3. Triple-negative breast cancer (TNBC) defined as histologically confirmed diagnosis of breast cancer and must have received at least 1 chemotherapy-containing regimen for advanced disease (recurrent or metastatic). Tumour must be triple-negative, defined as minimal or no expression of estrogen and progesterone receptors [<10% of cells positive by immunohistochemistry (IHC)], and minimal or no expression of HER2 (IHC staining 0 or 1+ or FISH-).
4. Small-cell lung cancer (SCLC) defined as a histologically confirmed diagnosis of SCLC and must have received at least 1 chemotherapy-containing regimen for advanced disease (recurrent or metastatic).

Exclusion criteria

1. Any chemotherapy within 3 weeks of the first dose of AZD1775, except hormonal therapy in the refractory cohort.

2. Use of a study drug ≤21 days or 5 half-lives, whichever is shorter.

3. Major surgical procedures ≤28 days, or minor procedures ≤7 days.

4. Grade >1 toxicity from prior therapy (except alopecia or anorexia).

5. CNS disease other than neurologically stable, treated brain metastases.

6. Prescription or non-prescription drugs or other products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued two weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug.

7. NYHA ≥ Class 2.

8. Mean resting corrected QT interval (QTc) ≥450 msec for males and ≥470 msec for females.

9. Pregnant or lactating.

10. Serious active infection, or serious underlying medical condition.

11. Presence of other active invasive cancers. 13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

92 participants in 1 patient group

AZD1775

Experimental group

Description:

Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle. This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types.

Treatment:

Drug: AZD 1775